Regeneron Pharmaceuticals
Change company
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
IN
IE
US
US
US
US
US
US
US
US
US
US
US
US
US
US
AU
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
BM
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
JP
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
CA
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
US
Regeneron Pharmaceuticals (REGN) Business News
Track Regeneron Pharmaceuticals in real time with a live news feed covering Regeneron Pharmaceuticals stock news, official press releases, company announcements, and an archive of historical Regeneron Pharmaceuticals news. ...more
-
CalendarDateSuMoTuWeThFrSaSelected FilterNo selection
2 Biotech Giants to Buy in 2026
2 Biotech Giants to Buy in 2026
Regeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Elo Mutual Pension Insurance Co Increases Stake in Regeneron Pharmaceuticals, Inc. $REGN
REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria
Compound Planning Inc. Invests $557,000 in Regeneron Pharmaceuticals, Inc. $REGN
10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)
Why Dupixent Keeps Regeneron A Top Big Pharma Pick
Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
Fox Run Management L.L.C. Acquires Shares of 4,413 Regeneron Pharmaceuticals, Inc. $REGN
2 Biotech Giants to Buy in 2026
Fool - Investing NewsBoth of these players are leaders in their fields.
Read full article
2 Biotech Giants to Buy in 2026
Fool - Investing NewsBoth of these players are leaders in their fields.
Read full article
Regeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Seeking AlphaRegeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Read full article
Elo Mutual Pension Insurance Co Increases Stake in Regeneron Pharmaceuticals, Inc. $REGN
Defense WorldElo Mutual Pension Insurance Co increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 23.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 13,431 shares of the biopharmaceutical company's stock after buying an additional 2,514 shares during the period. Elo
Read full article
REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in Urticaria
Zacks Investment ResearchRegeneron and Sanofi win CHMP backing to expand Dupixent use to young CSU patients, with EU and U.S. decisions poised to unlock a new growth avenue.
Read full article
Compound Planning Inc. Invests $557,000 in Regeneron Pharmaceuticals, Inc. $REGN
Defense WorldCompound Planning Inc. acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 990 shares of the biopharmaceutical company's stock, valued at approximately $557,000. Other large investors have also added to or reduced their stakes
Read full article
10 Best CEFs This Month: Average Yield Of 9.7% (February 2026)
Seeking AlphaThe article presents a rigorously screened list of 10 top closed-end funds, or CEFs, for income investors, offering an average 9.7% yield and -10% NAV discount. Selections emphasize sector diversification, long-term outperformance, sustainable distributions, and attractive valuations, with a focus on both equity and credit-oriented CEFs. CEFs are generally characterized by higher volatility and deeper drawdowns than the broader market. For these reasons, they are not suited for everyone.
Why Dupixent Keeps Regeneron A Top Big Pharma Pick
Seeking AlphaRegeneron Pharmaceuticals ended 2025 and started this year on a high note. Regeneron and its partner Sanofi are among the leaders in the immune-mediated inflammatory diseases market. In Q4, Dupixent sales grew 22.8% year-on-year and 2.2% quarter-on-quarter to about €4.
25 billion.
Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
GlobeNewsWireSanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Read full article
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
GlobeNewsWireIf approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment
Read full article
Fox Run Management L.L.C. Acquires Shares of 4,413 Regeneron Pharmaceuticals, Inc. $REGN
Defense WorldFox Run Management L.L.C. bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission.
The fund bought 4,413 shares of the biopharmaceutical company's stock, valued at approximately $2,481,000. Regeneron Pharmaceuticals comprises about